Paper35166158
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N and 6 others. J Psychopharmacol, 2022. Cited by 286 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Papers, record 35166158. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35166158
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antidepressive Agents | Major topic |
| Major Depressive Disorder | Major topic |
| Hallucinogens | Major topic |
| Psilocybin | Major topic |
| Adult | |
| Aged | |
| Combined Modality Therapy | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Psychiatric Status Rating Scales | |
| Psychotherapy | |
| Time Factors | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| T32 DA007209 | NIDA NIH HHS | United States | T32DA007209 | PubMed and NIH |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT06303739 | Psilocybin-Assisted Therapy in Treatment-Resistant Depression | Background | ClinicalTrials.gov | |
| NCT07710027 | Identification of a Safe and Non-Psychedelic Dose of Psilocybin | Background | ClinicalTrials.gov |
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29753748 | The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. | Neuropharmacology | 2018 | https://conductscience.org/library/papers/29753748 | PubMed |
| 2 | 26926127 | Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. | Am J Psychiatry | 2016 | https://conductscience.org/library/papers/26926127 | PubMed |
| 3 | 25563443 | Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. | Curr Drug Abuse Rev | 2014 | https://conductscience.org/library/papers/25563443 | PubMed |
| 4 | 32864325 | Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. | J Contextual Behav Sci | 2020 | https://conductscience.org/library/papers/32864325 | PubMed |
| 5 | 27261367 | Ketamine abuse potential and use disorder. | Brain Res Bull | 2016 | https://conductscience.org/library/papers/27261367 | PubMed |
| 6 | 30496104 | Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. | Lancet | 2018 | https://conductscience.org/library/papers/30496104 | PubMed |
| 7 | 19045960 | Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. | J Consult Clin Psychol | 2008 | https://conductscience.org/library/papers/19045960 | PubMed |
| 8 | 33726522 | Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. | Am J Psychiatry | 2021 | https://conductscience.org/library/papers/33726522 | PubMed |
| 9 | 32500212 | Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. | Psychopharmacology (Berl) | 2020 | https://conductscience.org/library/papers/32500212 | PubMed |
| 10 | 32061748 | Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. | Behav Brain Res | 2020 | https://conductscience.org/library/papers/32061748 | PubMed |
| 11 | 17640154 | Prevalence and management of treatment-resistant depression. | J Clin Psychiatry | 2007 | https://conductscience.org/library/papers/17640154 | PubMed |
| 12 | 27909164 | Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. | J Psychopharmacol | 2016 | https://conductscience.org/library/papers/27909164 | PubMed |
| 13 | 28013125 | The effect of treatment as usual on major depressive disorder: A meta-analysis. | J Affect Disord | 2017 | https://conductscience.org/library/papers/28013125 | PubMed |
| 14 | 10671391 | Multiple recurrences of major depressive disorder. | Am J Psychiatry | 2000 | https://conductscience.org/library/papers/10671391 | PubMed |
| 15 | 29020861 | Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. | J Psychopharmacol | 2018 | https://conductscience.org/library/papers/29020861 | PubMed |
| 16 | 21820991 | Prevalence and clinical course of depression: a review. | Clin Psychol Rev | 2011 | https://conductscience.org/library/papers/21820991 | PubMed |
| 17 | 18593735 | Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. | J Psychopharmacol | 2008 | https://conductscience.org/library/papers/18593735 | PubMed |
| 18 | 18593734 | Human hallucinogen research: guidelines for safety. | J Psychopharmacol | 2008 | https://conductscience.org/library/papers/18593734 | PubMed |
| 19 | 33852780 | Trial of Psilocybin versus Escitalopram for Depression. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33852780 | PubMed |
| 20 | 33146667 | Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. | JAMA Psychiatry | 2021 | https://conductscience.org/library/papers/33146667 | PubMed |
Cited by159
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 286 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42900476 | Clinical Evidence on Psilocybin and Its Representation in Media Reporting: A Systematic Review. | JAMA Netw Open | 2026 | https://conductscience.org/library/papers/42900476 | PubMed |
| 42818834 | Exploring the potential of psychedelics in brain injury recovery: a thematic analysis of participant narratives. | Front Neurol | 2026 | https://conductscience.org/library/papers/42818834 | PubMed |
| 42812990 | Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42812990 | PubMed |
| 42794483 | Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794483 | PubMed |
| 42653026 | Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42653026 | PubMed |
| 42506248 | Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions. | J Fungi (Basel) | 2026 | https://conductscience.org/library/papers/42506248 | PubMed |
| 42504298 | Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review. | Ther Adv Psychopharmacol | 2026 | https://conductscience.org/library/papers/42504298 | PubMed |
| 42357539 | DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish. | Molecules | 2026 | https://conductscience.org/library/papers/42357539 | PubMed |
| 42350785 | Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. | Mol Psychiatry | 2026 | https://conductscience.org/library/papers/42350785 | PubMed |
| 42346087 | Sex Differences in Depression: Adult Cytogenesis as Potential Target for Precision Psychiatry. | Cells | 2026 | https://conductscience.org/library/papers/42346087 | PubMed |
| 42342649 | Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care. | Transl Psychiatry | 2026 | https://conductscience.org/library/papers/42342649 | PubMed |
| 42201843 | Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial. | Psychother Psychosom | 2026 | https://conductscience.org/library/papers/42201843 | PubMed |
| 42196212 | Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196212 | PubMed |
| 42138922 | Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial. | JAMA Netw Open | 2026 | https://conductscience.org/library/papers/42138922 | PubMed |
| 42093782 | Catatonia Associated With First-Time Psilocybin Exposure: A Case Report. | Cureus | 2026 | https://conductscience.org/library/papers/42093782 | PubMed |
| 41969367 | Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. | Nat Ment Health | 2024 | https://conductscience.org/library/papers/41969367 | PubMed |
| 41918771 | A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations. | Ther Adv Psychopharmacol | 2026 | https://conductscience.org/library/papers/41918771 | PubMed |
| 41854988 | Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies. | Discov Ment Health | 2026 | https://conductscience.org/library/papers/41854988 | PubMed |
| 41828429 | Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41828429 | PubMed |
| 41707717 | Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial. | J Affect Disord | 2026 | https://conductscience.org/library/papers/41707717 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GRAP2 | 9402 | PubTator's text mining | https://conductscience.org/library/genes/9402 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35166158
GET https://conductscience.org/api/papers/v1/35166158/references?page=2